Shattuck Labs (NASDAQ:STTK) Insider Arundathy Pandite Sells 30,000 Shares

Shattuck Labs, Inc. (NASDAQ:STTK) insider Arundathy Pandite sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $6.61, for a total value of $198,300.00. Following the transaction, the insider directly owned 166,219 shares in the company, valued at approximately $1,098,707.59. This represents a 15.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shattuck Labs Trading Down 1.2%

Shares of NASDAQ STTK opened at $6.67 on Friday. The stock has a market cap of $511.46 million, a price-to-earnings ratio of -10.59 and a beta of 1.18. Shattuck Labs, Inc. has a 1-year low of $0.71 and a 1-year high of $8.33. The stock’s 50-day moving average is $6.61 and its 200 day moving average is $4.46.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. During the same period in the previous year, the firm earned ($0.27) EPS. On average, analysts forecast that Shattuck Labs, Inc. will post -0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Piper Sandler assumed coverage on Shattuck Labs in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price target on the stock. Cantor Fitzgerald assumed coverage on Shattuck Labs in a research note on Monday, April 27th. They issued an “overweight” rating on the stock. Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. Finally, Citigroup lifted their price target on Shattuck Labs from $4.00 to $7.00 and gave the stock a “neutral” rating in a research note on Friday, March 13th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Institutional Investors Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new position in Shattuck Labs during the third quarter valued at $15,072,000. NEXTBio Capital Management LP purchased a new position in shares of Shattuck Labs in the 4th quarter worth about $11,497,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Shattuck Labs in the 4th quarter worth about $7,031,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 1.8% in the 3rd quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock worth $3,319,000 after purchasing an additional 25,000 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Shattuck Labs in the 4th quarter worth about $4,945,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.